LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/People In The News/Carlozzi, of Integra, Dies At 56
People In The News

Carlozzi, of Integra, Dies At 56

December 28, 2012 2 min read Premium comments

Advertisement

Carlozzi, of Integra, Dies At 56
Gerry Carlozzi

Gerard S. Carlozzi, 56, the former executive vice-president and chief operating officer of Integra LifeSciences Corporation, died on Christmas Day, 2012, at Jefferson University Hospital, Philadelphia. Carlozzi died of pancreatic cancer. He is survived by his wife Kathy, with whom he shared 35 years of marriage, four children, Brian, Christine, Stephanie and Nicole, and two brothers and a sister. Funeral services will be held on December 29 at St. Peter Church, West Brandywine, Massachusetts.

Anthony Viscogliosi, of Viscogliosi Brothers LLC, told OTW, “Marc, John and I had the good fortune and blessing to know Gerry for at least 15 years. Gerry was dear to us all as a cherished friend, colleague, business partner, board member, competitor, mentor, guide and counselor. He was always true, fair, spoke from the heart, was really committed to what he believed and gave his all. A kind and giving man in every way.”

In 1979 Carlozzi joined InfusAid, Inc. where he helped develop implantable devices that delivered chemotherapy drugs to patients. He credits the time spent with surgeons with giving him the insight he needed to understand problems and devise solutions. “It was a great experience to watch them operate and listen to them explain what they were doing and why they were doing it, ” he said.

" data-large-file="https://i0.wp.com/ryortho.com/wp-content/uploads/2012/12/Carlozzi_Gerry_WEB2.jpg?fit=730%2C497&ssl=1" src="https://i0.wp.com/ryortho.com/wp-content/uploads/2012/12/Carlozzi_Gerry_WEB2.jpg?resize=300%2C204&ssl=1" alt="" height="204" width="300">
Gerry Carlozzi / Courtesy of Integra LifeSciences Corporation

Carlozzi earned an MBA from Northeastern and moved to Acufex Micosurgical, Inc., a start-up medical device company owned by American Cyanamid. During his tenure there the company grew from $7 million in revenues to over $60 million. Carlozzi joined Synthes, Inc. in 1995 and in 1998 he was recruited to head up Bionx Implants, Inc., his first experience at the helm of a publicly-traded company.

“We had about six months of operating cash when I arrived at the business. We were able to achieve positive cash flow and go from declining sales to a 20 percent growth rate in the course of a year.” After five years with Bionx, Carlozzi left to become the Chief Operating Officer of Integra LifeSciences.

Of his work at Integra LifeSciences, Stuart Essig, chairman of the Board of Directors, said, ” Gerry led in a firm, straightforward and mentoring manner and was an excellent leader. Gerry’s steady hand and calmness under fire guaranteed that we remained centered and focused on our core goals. His vast experience provided timely wisdom to the rest of us. I was honored to work alongside Gerry for eight years. His tireless efforts and determination helped Integra grow dramatically.”

Carlozzi served on the executive boards of various companies in the medical device industry. He enjoyed golf, fishing and going on long walks with his dog Bailey. Memorial contributions may be made in his name to Johns Hopkins University for Pancreatic Cancer Research and sent to Ralph H. Hruban, M.D., Johns Hopkins Medical Institutions, 401 North Broadway, Baltimore, Maryland, 21231-2410.

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy